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Abstract
Non-steroidal anti-inflammatory drugs such as diclofenac exhibit potent anticancer effects. Up to now these effects were
mainly attributed to its classical role as COX-inhibitor. Here we show novel COX-independent effects of diclofenac.
Diclofenac significantly diminished MYC expression and modulated glucose metabolism resulting in impaired melanoma,
leukemia, and carcinoma cell line proliferation in vitro and reduced melanoma growth in vivo. In contrast, the non-selective
COX inhibitor aspirin and the COX-2 specific inhibitor NS-398 had no effect on MYC expression and glucose metabolism.
Diclofenac significantly decreased glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and monocarboxylate
transporter 1 (MCT1) gene expression in line with a decrease in glucose uptake and lactate secretion. A significant
intracellular accumulation of lactate by diclofenac preceded the observed effect on gene expression, suggesting a direct
inhibitory effect of diclofenac on lactate efflux. While intracellular lactate accumulation impairs cellular proliferation and
gene expression, it does not inhibit MYC expression as evidenced by the lack of MYC regulation by the MCT inhibitor a-
cyano-4-hydroxycinnamic acid. Finally, in a cell line with a tetracycline-regulated c-MYC gene, diclofenac decreased
proliferation both in the presence and absence of c-MYC. Thus, diclofenac targets tumor cell proliferation via two
mechanisms, that is inhibition of MYC and lactate transport. Based on these results, diclofenac holds potential as a clinically
applicable MYC and glycolysis inhibitor supporting established tumor therapies.
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Introduction
The transcription factor MYC plays a key role in the regulation
of cell growth, differentiation and apoptosis [1]. Normal cells are
characterized by low steady state levels of MYC expression. This
tight control is lost in many human malignancies leading to high
constitutive expression of MYC. The inactivation of MYC can
revert the neoplastic phenotype in tumor model [2]. Therefore,
MYC represents an attractive target for cancer therapy in humans
[3;4], but currently no MYC inhibitor other than dexamethasone
is clinically applicable.
Overexpression of MYC leads to the upregulation of glycolytic
enzymes such as glucose transporter-1 (GLUT1) and lactate
dehydrogenase-A (LDHA) [5;6]. High rates of glucose uptake and
glycolysis are characteristic for human cancers, a feature already
described by Otto Warburg almost a century ago [7–9]. High
lactate concentrations in the tumor correlate with malignancy [10]
and genetic downregulation of LDHA results in reduced tumor
growth in vivo [11;12]. Furthermore, pharmacological targeting of
glucose metabolism by 2-deoxyglucose (2-DG) and 3-bromopyr-
uvate (3-BrPA), both inhibitors of glycolysis, as well as dichlor-
oacetate (DCA), which targets the mitochondrial pyruvate
dehydrogenase kinase (PDK), has been shown to reduce tumor
growth in animal models [13–16]. In addition, silencing of the
lactate transporters (monocarboxylate transporter, MCT) by
shRNA in vitro and in vivo results in a reduction of cell viability
and tumor growth [17;18]. Lactate transport can also be blocked
by pharmacological means as non-steroidal anti-inflammatory
drugs (NSAIDs) have been shown to reduce the transport of lactate
in a human trophoblast cell line and chinese hamster ovary (CHO)
cells [19;20]. However, this effect of NSAIDs has never been
addressed with regard to inhibition of tumor growth, although
several epidemiological studies report that the use of NSAIDs is
linked to a lower risk of inflammation-associated tumors like colon,
oesophagus and breast cancer [21;22]. The relationship between
chronic inflammation and cancer has already been described by
Virchow in 1863 and is still accepted as an important component
of tumor development [23]. Anti-tumor effects of NSAIDs have
been attributed mainly to the inhibition of cyclooxygenase
(COX1/2) and their anti-inflammatory effects, albeit COX-
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independent inhibition of tumor cell proliferation and induction of
apoptosis have been also reported [24;25]. In addition, it has been
known for years, that NSAIDs affect mitochondrial activity and
function and this aspect has recently been linked to its anti-
proliferative effect on tumor cells [26;27].
Here, we show a novel COX-independent effect of the NSAID
diclofenac on human and murine tumor cells via reduction of
MYC, glucose uptake and lactate secretion. Since tumor cell
proliferation was diminished in vitro and growth of subcutaneous
tumors was impaired in vivo, diclofenac might be used as a novel
anti-cancer drug supporting established tumor therapies.
Materials and Methods
Chemicals and Drugs
All drugs were purchased from Sigma (Taufkirchen, Germany)
and dissolved in water, unless otherwise indicated. The sodium salt
of diclofenac, acetylsalicylic acid (aspirin, ASA) (both from Fagron,
Barsbu¨ttel, Germany), NS-398, gemcitabine (Hospira, Munich,
Germany), and alpha-cyano-4-hydroxycinnamic acid (CHCA)
(Sigma) were dissolved in medium.
Cells and Cell Culture
The human melanoma cell line MelIm [28] was obtained from
Judith Johnson, Institute for Immunology, Munich, Germany, in
1993 and has been tested in the last 3 months for melanocyte
markers and melanoma markers by RT-PCR. B16 subclone of
B16F10 mouse melanoma [29]. The human histiocytic leukemia
cell line U937 was purchased from DSMZ (German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany). B16
and U937 were identified by DSMZ in May 2011. The prostate
carcinoma line PC3 and the T-cell leukemia cell line Jurkat were
purchased from ATCC. P493-6, a B cell line carrying a
conditional, tetracyclin-regulated MYC gene, was provided by
G. W. Bornkamm Munich, Germany [30]. All cell lines were
cultured in RPMI 1640, 10% fetal calf serum (both from PAN
Biotech, Germany), 2 mM glutamine, 50 U/mL penicillin/50 mg/
mL streptomycin (all from Gibco) at 5% CO2 and 37uC. For
suppression of MYC, P493-6 cells were treated with 1 mg/mL
tetracycline for 24 h before diclofenac treatment.
Monocytes were obtained by leukapheresis of healthy donors,
followed by density gradient centrifugation over Ficoll/Hypaque
and separation by countercurrent centrifugation (J6M-E centri-
fuge; Beckmann, Munich, Germany). Monocytes were cultured at
a concentration of 16106 cells/ml for 48 h in RPMI 1640, 10%
fetal calf serum (both from PAN Biotech, Germany), 2 mM
glutamine, 50 U/mL penicillin/50 mg/mL streptomycin (all from
Gibco) and 100 ng/ml LPS at 5% CO2 and 37uC in teflon bags
with or without the addition of diclofenac.
Determination of Cell Proliferation
36104 cells/0.2 mL medium were incubated for 22 h with
diclofenac, ASA or gemcitabine in 96-well plates. [3H]-thymidine
incorporation was determined 24 h after the addition of 0.5 mCi/
0.2 mL [3H]-thymidine (Amersham Pharmacia, Piscataway, NJ).
Determination of Apoptosis
For analysis of apoptosis, diclofenac treated cells were stained
with Annexin-V-FITC and 7-aminoactinomycin D (7-AAD) (both
from BD Biosciences, San Jose, CA) according to the manufac-
turer’s instructions. Flow cytometric analyses were performed on a
FACSCalibur (BD Biosciences) using BD CellQuestPro for data
acquisition and analysis.
Subcutaneous Tumor Mouse Model
Animal experiments were approved by the Institutional Animal
Care and Use Committee of the University of Regensburg and
regional authorities. In brief, 16105 cells of B16 were subcutane-
ously injected into the right flank of C57/BL6 mice (Charles
River, Sulzfeld, Germany). Mice were randomized and assigned to
treatment groups (n = 7/group). Once tumor volumes reached 50–
80 mm3 (day 14), mice received diclofenac (15 mg/kg) or saline
via intraperitoneal (i.p.) injection every other day until termination
of the experiment on day 23. 15 mg/kg diclofenac corresponds
approximately to 0.5 mM used for in vitro assays. Tumor
diameters were measured with calipers and tumor volumes were
calculated (width26 length60.5).
Determination of Lactate in Tumor Cell Supernatants
Cells were seeded at a concentration of 26105 cells/2 mL
medium with or without diclofenac, ASA or gemcitabine. After
48 h, lactate levels in cell culture supernatants were determined by
means of an ADVIA1650 analyzer (Bayer, Tarrrytown, NY) using
reagents from Roche (Mannheim, Germany) at the Department of
Clinical Chemistry, University Clinic, Regensburg, Germany.
Western Blotting
2,56106 cells/4 mL medium were cultured in 6-well plates over
night. Whole cell lysates were prepared with RIPA-buffer and
samples (50 mg) were subjected to western blotting on a
denaturating 10% SDS-PAGE. Membranes were sequentially
probed with antibodies against MYC (#9402, Cell Signaling
Technologies, Beverly, MA), STAT3 (Cell Signaling Technolo-
gies, Beverly, MA), HIF-1a (sc-10790, Santa Cruz Biotechnolo-
gies, Santa Cruz, CA), HIF-2a (NB100-132, Novus Biologicals,
Littleton, CO) or b-Actin (Santa Cruz Biotechnologies, Santa
Cruz, CA) in dry milk (5%) and detection was performed by
chemoluminescence (ECL, Amersham Bioscience, Piscataway,
NJ). Densitometric analyses were performed by means of the
ChemiDoc MP Imaging System and the Image LabTM software
(Bio-Rad Laboratories, Hercules, CA).
Promoter Assay
The region upstream the transcription start site of human MYC
(2632bp, chr8:128746062-128748693) was amplified from geno-
mic DNA and cloned into the Luciferase Reporter Vector pGL4
(Promega). MelIm were cotransfected in 6-well-plates with the
luciferase construct or the empty pGL4 vector (Promega) and
cotransfected with an internal control vector (phRL-TK, Promega)
using LipofectamineTM 2000 (Invitrogen). Diclofenac was added
after 5 h at different concentrations. 24 h after transfection,
luciferase activity was determined in cell lysates using the Dual-
Luciferase-Reporter Assay System (Promega) according to the
manufacturer’s instructions. The activity was normalized by the
ratio of Firefly luciferase activity to Renilla luciferase activity
(internal control) and compared to pGL4 empty vector.
RNA Isolation and Quantification of mRNA Expression
2.56106 cells/4 mL medium were incubated for 24 h in 6-well
plates. Total RNA was isolated using the RNeasy Mini Kit
(Qiagen, Germany). After reverse transcription using M-MLV
reverse transcriptase (Promega, Germany), products were ana-
lyzed on a Mastercyler Ep Realplex (Eppendorf, Germany) using
the QuantiFast SYBR Green PCR Kit (Qiagen, Germany).
Expression data were normalized to the housekeeper 18S rRNA.
Primers used were 59-39:
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18S rRNA sense: ACCGATTGGATGGTTTAGTGAG; 18S
rRNA antisense: CCTACGGAAACCTTGTTACGAC; GLUT1





For determination of glucose levels in cell culture supernatants,
cells were cultured at 26106 cells/4 mL medium with or without
diclofenac for 48 h. 1D and 2D NMR spectra of the filtered
supernatants were measured on a 600 MHz Bruker Avance III
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) as
described previously [31].
Gas Chromatography – Mass Spectrometry (GC-MS)
U937 cell pellets, washed 3 times with PBS, were extracted
using 2 mL 80% methanol. MelIm cells were harvested by
directed scraping with 80% methanol as described before [32].
During extraction, samples were spiked with 10 mL of a surrogate
solution containing [U-13C]lactate (Euriso-top, Saint-Aubin Ce-
dex, France) and [2H4]diclofenac (CDN Isotopes Inc., Quebec,
Canada) at a concentration of 1 mM each.
Dried sample extracts were analyzed by GC-MS in full scan
mode [33]. Quantification of lactate was performed using
calibration curves and diclofenac by stable isotope dilution using
the mass trace of m/z 214 for diclofenac and m/z of 218 for
[2H4]diclofenac.
Respirometry
Activity of the respiratory system was analyzed in a two-channel
titration injection respirometer (Oxygraph-2k, Oroboros, In-
nsbruck, Austria) at 37uC. Cells were resuspended in fresh culture
medium and added to the chamber. After a stabilization phase of
15 to 20 min, ROUTINE respiration of intact cells was measured,
complex V was inhibited by oligomycin (2 mg/mL), and subse-
quently the capacity of the electron transfer system (ETS) was
determined after uncoupling with FCCP (2.5 mM). Residual
oxygen consumption was determined after addition of rotenone
(complex I inhibitor, 0.1 mM) and antimycin A (complex III
inhibitor 2.5 mM) and subtracted from all respiratory parameters.
Statistical Analysis
All results represent mean +/2 standard deviation (SD) of at
least three independent experiments. Statistical analysis was
performed with unpaired, two-tailed Student’s t-test,
***p,0.001; **p,0.01; *p,0.05. For western blots, one repre-
sentative experiment is shown.
Results
Diclofenac inhibits melanoma cell proliferation in vitro
The addition of diclofenac, which is a member of the arylacetic
acid group of NSAIDs, at clinically relevant concentrations (see
http://www.drugs.com/pro/diclofenac.html) led to significant
effects on several tumor cell lines starting at concentrations as
low as 0.1 mM. The proliferation of the human melanoma cell
line MelIm was inhibited significantly (p,0.001) at 0.4 mM
diclofenac (Fig. 1A) and reduction in proliferation was comparable
to that of the standard chemotherapeutic drug gemcitabine
(Fig. S1A In contrast, aspirin (ASA), a typical NSAID exerted
no impact on proliferation indicating a COX-independent effect
of diclofenac (Fig. 1B). Other NSAIDs like the COX-2 specific
inhibitor NS-398 (Fig. 1C), as well as 4-ASA and 5-ASA (data not
shown) also exerted no significant impact on tumor cell
proliferation. To clarify whether the effect of diclofenac on
proliferation is based on the induction of cell death, we analyzed
viable and apoptotic cells after incubation with diclofenac in
MelIm. Only 0.8 mM diclofenac exerted a slight but significant
effect on the number of dead cells after 24 h (Fig. 1D).
Diclofenac inhibits MYC expression in melanoma cells
It is well known, that tumor cell proliferation is associated with
an upregulation of oncogenes like MYC and that the inactivation
of MYC can revert the neoplastic phenotype and induce apoptosis
[2]. Therefore, we analyzed the expression of MYC protein under
the administration of diclofenac by western blot analysis. After 2 h
and 24 h, we observed a clear reduction in MYC protein level in
MelIm cells (Fig. 1E/F and Fig. S2A) which coincided with the
inhibition of proliferation. In contrast, ASA did not affect MYC
expression (Fig. 1G). The protein expression of other transcription
factors, namely STAT3, a known critical regulator of melanoma
development [34], and HIF-1a and HIF-2a, respectively, were not
influenced by diclofenac (Fig. 1F). As Zhu et al. had described
modulating, albeit stimulatory effects of indomethacin not only on
MYC protein but also on MYC gene expression [35], we
performed a MYC promoter assay. We cloned a region of about
2.6 kb upstream the transcription start site of human MYC into
the Luciferase Reporter Vector pGL4 and transfected the plasmid
into MelIm. As shown in Figure 1H, diclofenac suppressed MYC
promoter activity significantly.
Diclofenac inhibits MYC expression and proliferation in
leukemia and carcinoma cells
To confirm that the effect of diclofenac on proliferation and
MYC expression was not restricted to melanoma cells, we
analysed its impact on the human histiocytic lymphoma cell line
U937. Again, we found a significant inhibition of proliferation and
MYC expression by diclofenac (Fig. 2A/ 2B and Fig. S2A)
whereas aspirin (ASA) did not show an effect (Fig. 2C). Similar
results were obtained with other tumor cell lines such as the
prostate carcinoma cell line PC3 (Fig. 2A/B) and the T-cell
leukemia cell line Jurkat (data not shown). In the myeloid leukemia
cell line U937, diclofenac concentrations up to 0.4 mM only
slightly reduced the number of viable cells after 24 h (about 80%
viable cells left). This effect was more pronounced after 72 h
reducing the number of viable cells to 45% and 31% for 0.1 mM
and 0.2 mM, respectively (Fig. 2D). In contrast, the viability of
non-malignant blood monocytes was not impaired even after
prolonged incubation at these concentrations (Figure 2E).
Diclofenac inhibits tumor cell proliferation in vivo
To demonstrate an in vivo effect of diclofenac, we switched to the
mouse melanoma cell line B16. Diclofenac reduced proliferation
significantly at concentrations of 0.2 mM and higher (Fig. 3A).
Diclofenac also decreased MYC expression in a time- and dose-
dependent fashion. Densitometric analyzes revealed that MYC
protein was reduced starting at 0.2 mM diclofenac after 2 h
incubation. This effect was more pronounced after 24 h, however
a strong reduction was only detected at 0.4 mM and higher
(Fig. 3B and Fig. S2B). Next we analyzed the effect of diclofenac
on B16 tumor growth in vivo employing a syngeneic subcutaneous
mouse model. On day 14, after tumors had reached a volume of
50–80 mm3, diclofenac (15 mg/kg) or saline were injected
intraperitoneally every other day. Tumor growth was significantly
impaired already after 3 days of diclofenac treatment (Fig. 3C),
and so was the final tumor weight (Fig. 3D).
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Diclofenac inhibits glucose uptake and lactate secretion
in tumor cells
Given the known promoting effect of MYC on glycolysis [5], we
analyzed glucose metabolism in different cell lines. First, we
analyzed glucose consumption in the presence of diclofenac. After
24 h and 48 h we found a significant inhibition of glucose uptake
in MelIm already at 0.1 mM diclofenac (Fig. 4A). In most tumor
cells, glucose is predominantly metabolized to lactate [8]. Lactate
has to be secreted to avoid intracellular accumulation and
acidification, which blocks ATP generation via glycolysis. We
determined lactate in the supernatant of diclofenac treated MelIm,
Figure 1. In vitro effects of diclofenac on proliferation and MYC expression in the human melanoma cell line MelIm. The human
melanoma cell line MelIm was incubated with different concentrations of diclofenac (A), aspirin (ASA, B), and NS-398 (C), respectively, and
proliferation was determined after 24 h. Results represent the mean +/2 standard deviation of 12 (diclofenac) and 3 (ASA, NS-398) independent
experiments, respectively. (D) MelIm were incubated for 24 h with or without diclofenac. Apoptotic cells were stained with Annexin-V-FITC/ 7-AAD
and analyzed by flow cytometry. Results represent the mean +/2 standard deviation of 3 independent experiments. (E-G) MYC, STAT3, HIF1a and
HIF2a protein expression were determined in cell lysates of MelIm incubated for 2 or 24 h with or without diclofenac (E,F) or ASA (G). The effect of
diclofenac on MYC promoter activity was determined by transient transfection of a 2632-bp MYC promoter fragment (H). MelIm were transfected in
6-well-plates and diclofenac was added after 5 h. Luciferase activity was determined 24 h after transfection. Results represent the mean +/2 standard
deviation of 3 independent experiments.
doi:10.1371/journal.pone.0066987.g001
Figure 2. Effects of diclofenac on different tumor cell lines. (A) U937 and PC3 were incubated with increasing concentrations of diclofenac
and proliferation was determined after 24 h. Results represent the mean +/2 standard deviation of at least 3 independent experiments (PC3: 0.8
n = 2). (B) MYC protein expression was analyzed by western blotting in cell lysates of U937 and PC3 after 24 h incubation with diclofenac. (C) U937
was incubated with increasing concentrations of aspirin (ASA) and proliferation was determined after 24 h. Results represent the mean +/2 standard
deviation of 3 independent experiments. (D) U937 were incubated for 24 h up to 72 h with or without diclofenac and stained with Annexin-V-FITC/7-
AAD. Results represent the mean +/2 standard deviation of percentage of viable cells (Annexin-V-FITC/7-AAD negative cells) of 3 independent
experiments. (E) Freshly isolated human monocytes were cultured for 48 h in the presence or absence of diclofenac, stained with Annexin-V-FITC/7-
AAD and analysed by flow cytometry. Results represent the mean +/2 standard deviation of percentage of viable cells (Annexin-V-FITC/7-AAD
negative cells) and dead cells (Annexin-V-FITC/7-AAD positive cells) of 3 independent experiments.
doi:10.1371/journal.pone.0066987.g002
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B16 and U937. Compared to control, significantly lower
extracellular lactate levels were observed for MelIm at diclofenac
concentrations as low as 0.1 mM at 24 h and 48 h, respectively
(Fig. 4B). In contrast, neither aspirin (ASA) nor NS-398 (Fig. 4C)
affected extracellular lactate levels. Accordingly, B16 and U937
also yielded lower levels of extracellular lactate (Fig. 4D and 4E).
The effect of diclofenac was not due to a reduction in cell number,
as the classical chemotherapeutic drug gemcitabine inhibited
proliferation but not lactate secretion (Fig. S1A/B).
Diclofenac diminished glucose uptake and thereby substrate
delivery for mitochondrial respiration. Moreover, it was shown
that diclofenac inhibits pyruvate uptake into mitochondria.
Therefore, we measured mitochondrial respiration by high-
resolution respirometry at diclofenac concentrations that sufficed
to diminish glucose uptake but did not exhibit effects on
proliferation proliferation Immediately after addition of diclofenac
we detected an increase in basal respiration (ROUTINE) in both
cell lines (MelIm 54%, U937 39%). In U937 the increase in
respiration was the result of decoupling (detected by an equally
increase in oligomycin inhibited respiration) and was reversible. In
MelIm elevated respiratory activity was a combination of
increased activity coupled to ATP production and decoupling.
After 24 h of diclofenac treatment ROUTINE respiration and
oligomycin inhibited respiration were significantly suppressed in
U937 at 0.1 mM diclofenac and in MelIm at 0.2 mM diclofenac
(p,0.05, Fig. 4F). The capacity of the electron transfer system
showed the same tendency, but was statistically not significant.
Diclofenac blocks lactate transport and leads to
intracellular lactate accumulation
Next, we analyzed the cause of reduced extracellular lactate
levels upon treatment with diclofenac. Lactate is transported out of
the cell by monocarboxylate transporters (MCTs) that rely on a
concentration gradient of lactate and protons between the
extracellular and the intracellular compartment [36]. NSAIDs
with monocarboxylic acid structures such as diclofenac have been
reported to inhibit MCTs [19;37;38]. Quantitative RT-PCR
analysis revealed a constitutive expression of MCT1, glucose
transporter-1 (GLUT1) and lactate dehydrogenase A (LDHA) in
MelIm. The expression was upregulated after 24 h, which was
significantly prevented by diclofenac treatment (Fig. S3A-C). We
hypothesized, that diclofenac blocked efflux of lactate. Indeed, gas
chromatography-mass spectrometry analysis revealed that starting
from 0.1 mM, diclofenac is significantly taken up by MelIm and
U937 after 1 h (Fig. 5A and S4A), which was paralleled by a
marked intracellular accumulation of lactate (Fig. 5B and S4B).
MCT inhibition blocks lactate transport but has no effect
on MYC expression
The small-molecule competitive inhibitor of MCT, a-cyano-4-
hydroxycinnamic acid (CHCA), showed effects comparable to
diclofenac. As expected, the inhibitor blocked lactate transport as
shown by lowered extracellular levels of lactate upon incubation of
MelIm with CHCA (Fig. 5C) and led to an intracellular
accumulation of lactate (Fig. 5D). Concomitantly, glucose uptake
was inhibited (Fig. 5E). In addition, comparable to diclofenac,
Figure 3. In vitro and in vivo effects of diclofenac on proliferation of B16 murine melanoma cells. (A) Proliferation of B16 cells was
determined in the presence or absence of diclofenac after 24 h incubation. Results represent the mean +/2 standard deviation of 4 independent
experiments. (B) MYC expression was determined in B16 after incubation with diclofenac for 2 h and 24 h by western blotting. (C/D) For the analysis
of in vivo effects of diclofenac on tumor growth, 16105 B16 cells were injected subcutaneously into C57/BL6 mice. At a tumor volume of 50–80 mm3
(day 14), mice received diclofenac (15 mg/kg, n = 7) or saline (control, n = 7) via intraperitoneal injection every other day. The tumor weight was
determined on day 23 after termination of the experiment (D). Statistical analysis was performed with unpaired, two-tailed Student’s t-test,
***p,0.001; **p,0.01; *p,0.05.
doi:10.1371/journal.pone.0066987.g003
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administration of CHCA at 6 mM and higher caused a strong
inhibition of tumor cell proliferation (Fig. 5F). To test whether the
inhibition of MCTs and the resulting accumulation of lactate were
responsible for the regulation of MYC, we analysed MYC
expression after incubation of MelIm with CHCA. In contrast to
diclofenac, CHCA did not inhibit MYC expression (Fig 5G).
Diclofenac blocks tumor cell proliferation via MYC-
dependent and -independent mechanisms
Our data indicate two independent effects of diclofenac on
tumor cells that result in the inhibition of proliferation. To
distinguish the relevance of MYC suppression and block of lactate
transport on proliferation, we used human P493-6 B-cells, which
are derived from human peripheral blood B cells immortalized by
an Epstein–Barr viral (EBV) genome that is complemented with
an EBV nuclear antigen-estrogen receptor (EBNA2-ER) fusion
protein and a tetracycline-repressible MYC transgene [30]. In the
absence of tetracycline and estradiol, ectopic MYC is induced at
high levels, whereas with tetracycline only very low levels of MYC
are expressed [39]. Concordingly, in the presence of tetracycline
proliferation was about 2.5-fold lower than in its absence (Fig. 6A).
Upon addition of increasing concentrations of diclofenac, prolif-
eration decreased increasingly, albeit much more significantly in
MYC overexpressing cells. In the absence of detectable MYC
expression, lactate secretion was about 4-fold lower than in MYC
overexpressing cells (Fig. 6B). Increasing concentrations of
diclofenac inhibited significantly lactate secretion in MYC
overexpressing cells, with extracellular levels of lactate approach-
Figure 4. Diclofenac decreases glucose consumption and modulates lactate accumulation. (A) Glucose levels were determined in MelIm
supernatants after 24 h and 48 h of incubation with diclofenac. ‘‘Medium’’ represents the glucose concentration in the culture medium without cells.
Lactate was determined in cell culture supernatants of MelIm after 24 h and 48 h with or without diclofenac,(B) ASA or NS-398 (C). Lactate was
determined in cell culture supernatants of B16 after 48 h (D). Lactate levels were determined in supernatants of U937 (E) after incubation with
increasing concentrations of diclofenac for 48 h. Results represent the mean +/2 standard deviation of 3 independent samples. Diclofenac reduced
mitochondrial activity in both cell lines after 24 h (F). A reduction of about 40% was observed in MelIm at a concentration of 0.2 mM and in U937 at a
concentration of 0.1 mM. Basal mitochondrial activity (ROUTINE), oligomycin inhibited respiration and capacity of electron transfer system (complex I
to IV) were diminished by diclofenac. Results represent the mean+/2SD of 3 and 5 independent experiments, respectively, for MelIm and U937.
doi:10.1371/journal.pone.0066987.g004
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ing those observed in cells treated with tetracycline. As observed
for MelIm, B16, and U937 cells, diclofenac reduced MYC protein
levels in MYC overexpressing P493-6 cells after 2 h and 24 h
(Fig. 6C). Further investigations will clarify whether this effect is
based on modulation of protein stability or transcriptional
regulation. These experiments confirm the ability of diclofenac
to inhibit lactate secretion and MYC expression at concentrations
of 0.1 mM and about 0.4 mM, respectively, with both effects
contributing to reduced proliferation.
Discussion
A hallmark of many cancer cells is an increased reliance on
glycolytic metabolism and the production of large amounts of
lactate regardless of the availability of oxygen. This so-called
Figure 5. Blocking lactate transport by CHCA inhibits proliferation and lactate secretion in MelIm, but has no effect on MYC
expression. The intracellular concentration of diclofenac in the cell lysates was determined after 1 h incubation (A). Intracellular lactate levels were
determined in cell lysates of MelIm after 1 h incubation with or without diclofenac (B). Results represent the mean +/2 standard deviation of 3
independent samples. Lactate was determined in cell culture supernatants of MelIm treated for 48 h with CHCA or diclofenac (C). Results represent
the mean +/2 standard deviation of 4 independent samples. Intracellular lactate levels were determined in cell lysates of MelIm after 1-h incubation
with CHCA (D). Glucose levels were determined in MelIm supernatants after 24 h incubation with CHCA (E). Proliferation of MelIm was determined
after 24 h in the presence or absence of CHCA (F). Results represent the mean +/2 standard deviation of 4 independent samples. MYC protein
expression was analyzed in cell lysates of MelIm after 24 h incubation with CHCA by western blotting (G). One representative blot is shown.
doi:10.1371/journal.pone.0066987.g005
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‘‘Warburg effect’’ can be the result of biochemical and genetic
alterations [40] such as HIF1 stabilization [41], loss of p53 [42] or
a target gene of p53 [43], mutation of KRAS/BRAF [44] or
overexpression of MYC [5]. Drugs targeting key control points of
glycolysis are subject of intense research as promising anticancer
agents. However, no drugs other than DCA and the synthetic
glucocorticoids dexamethasone and prednisolone are available as
glycolytic inhibitors for clinical use. Glucocorticoids are also potent
MYC inhibitors, but a plethora of deleterious side effects impede
their prolonged use. NSAIDs represent the most commonly used
class of medication worldwide. In the light of our findings,
diclofenac may represent an attractive novel inhibitor of glycolysis
and MYC, which could easily be integrated in clinical trials with
likely important implications in cancer therapy. However, NSAID
use can be associated with adverse side effects, e.g. liver and kidney
injury as well as gastrointestinal bleeding. Although the incidence
is low, it will be important to determine the risk of diclofenac
treatment in relation to its possible benefit [45–47].
It is well-known that NSAIDs affect tumor cell proliferation in
COX-dependent and independent ways. However, little is known
about their effect on glucose metabolism. We found a significant
decrease in glucose consumption and lactate secretion in different
tumor cell lines upon treatment with diclofenac. However, these
effects seemed not to be related to the classical COX inhibition, as
ASA had no impact on glucose metabolism and proliferation.
Others reported a reduction in lactate secretion in MCF-7 breast
cancer cells by ASA, albeit at a ten-fold higher concentration [48].
The anti-proliferative effect, however, was not responsible for the
decreased glucose consumption and lactate secretion, as the
classical chemotherapeutic drug gemcitabine strongly decreased
proliferation without any effect on lactate secretion.
Besides the in vitro effects on melanoma and histiocytic
lymphoma cell lines, we also observed a significant reduction in
tumor growth in a syngeneic melanoma mouse model. Effects of
diclofenac on tumor growth had been described before in a
murine fibrosarcoma model, two xenograft models with human
neuroblastoma cells and lung carcinoma cells, and in a rat model
of early colon carcinogenesis [49–52]. However, the authors
attributed the effect of diclofenac primarily to the regulation of
lipid metabolism and COX inhibition. In the light of our results,
diclofenac does not only target lipid metabolism but also glucose
metabolism in tumor cells leading to reduced tumor growth as
demonstrated recently in a mouse glioma model [53]. In this
model, diclofenac had a significant effect not only on tumor cells,
but also on tumor stromal cells, e.g. myeloid and lymphoid cells.
This is in line with reports by Mayorek et al. who studied the effect
of diclofenac in a murine model of pancreatic cancer. Here, the
effect on tumor growth was linked to downregulation of VEGF
and angiogenesis in the tumor [54]. As lactate is known to
stimulate VEGF production in macrophages, a reduction of
intratumoral lactate levels by diclofenac could contribute to the
diminished VEGF production and angiogenesis in this model
[54;55]. Furthermore, tumor-derived lactate is not only a
modulator of stromal cells in the tumor environment, but it can
also serve as a carbon source for fibroblasts and aerobic tumor
cells [56;57]. Therefore, intratumoral lactate levels influence
tumor growth via several pathways [58].
We identified two potential mechanisms underlying the
suppression of proliferation and glucose metabolism by diclofenac.
First, diclofenac inhibited lactate efflux and, consequently, caused
an intracellular accumulation of lactate. Lactate is transported via
proton-coupled monocarboxylate transporters (MCTs), that form
Figure 6. Contribution of MYC to suppression of proliferation by diclofenac. P493-6 cells were incubated first for 24 h in the presence of
tetracycline to suppress MYC expression. Cells were then treated with diclofenac for 24 h. Proliferation (A) was determined by 3[H]-thymidine
incorporation, while lactate (B) was determined in cell culture supernatants. Results represent the mean +/2 standard deviation of 3 independent
experiments. MYC protein expression was analyzed in cell lysates of P493-6 with or without tetracycline treatment for 24 h (C). Cells were then
treated with diclofenac for an additional 2 h and 24 h, respectively, and MYC expression was determined in cell lysates by western blotting. One
representative western blot is shown.
doi:10.1371/journal.pone.0066987.g006
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heterodimeric complexes with the glycoprotein CD147 [36;59].
Our data suggest, that diclofenac may target this transport system.
This is in line with reports from Emoto and Vellonen on NSAID-
mediated inhibition of lactate transport in a trophoblast cell line
and corneal epithelial cell lines [19;38]. Accordingly, application
of the competitive MCT inhibitor CHCA could reproduce the
effect of diclofenac, inhibiting both lactate secretion and prolifer-
ation. It is known, that CHCA not only targets MCT in the
plasma membrane but also in the mitochondrial membrane with
possible implications on mitochondrial functions [60]. In line with
these findings, we also detected a transient increased respiration
mainly due to uncoupling after short-term incubation with
diclofenac followed by a decreased respiration after 24 h.
Aspirin/ASA and other NSAIDs are known to uncouple
mitochondrial energy metabolism [26]. However, as diclofenac
and ASA both target mitochondria in a similar fashion but only
diclofenac affected MYC expression, we assume that the
regulation of oxidative metabolism had no impact on MYC
expression in our model system. However, the reduction in
mitochondrial activity might contribute to the anti-proliferative
effect of diclofenac on tumor cells and support the induction of
apoptosis as has been shown for T-cell lymphoma cells [27;61].
Interestingly, Pouysse´gur and coworkers recently showed, that
combined silencing of MTC1 and MCT4 significantly reduced
glycolytic flux and tumor growth in vivo [18]. These results clearly
show that lactate efflux, glycolysis and tumor growth are closely
related. Similar results were described by Mathupala et al., who
showed that downregulation of MCTs by small hairpin RNA
inhibited glycolysis and induced cell death in a glioma cell line
[17]. In addition, silencing of CD147, an accessory subunit of
MCT1/4, also inhibited malignant melanoma growth [62].
Besides the rapid block of lactate transport, we found a lack of
upregulation of MCT1 mRNA that might have contributed to the
described effect. But changes in gene transcription often do not
correlate with changes in protein levels or enzyme activity and we
cannot exclude that despite a significant downregulation of MCT1
mRNA levels, protein levels are not altered. Furthermore,
expression of GLUT1 and LDHA was significantly decreased by
diclofenac in a concentration-dependent manner indicating that
diclofenac not only targeted lactate transport but also exerted a
more global effect on glycolysis. This effect was already detectable
at very low concentrations of about 0.1 mM diclofenac. However,
in MelIm MYC expression was significantly decreased only at
higher concentrations of about 0.8 mM diclofenac. Therefore,
additional factors might be involved in the transcriptional
regulation of LDHA and GLUT1 (summarized in Table 1). High
concentrations of diclofenac strongly suppressed MYC protein
expression and promoter activity. This effect was not due to COX
inhibition, as aspirin did not suppress MYC expression. Further-
more, the inhibition of lactate transport seems not to be involved
in MYC regulation because CHCA did not change MYC
expression. In addition, intracellular lactate accumulation was
comparable for 0.2 mM and 0.8 mM diclofenac but MYC
regulation was significantly different. Downregulation of MYC
by diclofenac correlated with tumor cell proliferation. However,
induction of cell death was only detected at 0.8 mM diclofenac, a
level that completely suppressed MYC. At this high concentration,
diclofenac also completely suppressed MYC in the MYC
overexpressing cell line P493-6 indicating not only a transcrip-
tional effect but also an impact on protein stability. As inhibition of
proliferation was found in MYC overexpressing and non-
expressing P493-6, we concluded that diclofenac targeted prolif-
eration via both MYC-dependent and independent mechanisms.
MYC overexpressing P493-6 showed higher lactate secretion than
MYC non-expressing P493-6 and lactate levels were decreased in
both cell lines. This again indicated two independent mechanisms
of diclofenac.
Alterations in tumor energy metabolism exert significant effects
on tumor growth and metastasis and the use of glycolysis inhibitors
alone or in combination with chemotherapeutic drugs has been
suggested [63]. Furthermore, the rationale of targeting MYC has
been clearly demonstrated by Savino and Soucek [64;65], who
demonstrated that systemic Myc inhibition by Omomyc, a
dominant negative form of Myc, leads to a rapid regression of
established tumors [64]. Our findings, that diclofenac inhibits both
glucose metabolism and MYC expression, make this well
established drug an attractive candidate for inclusion in clinical
trials with likely important implications for cancer therapy.
Supporting Information
Figure S1 Gemcitabine inhibits proliferation and lac-
tate of the melanoma cell line Mellm.
(TIF)
Figure S2 Densitometric analyses of MYC protein
expression as a function of diclofenac concentration in
Mellm, PC3 and U937 after 24 h.
(TIF)
Figre S3 Diclofenac inhibits MCT1, GLUT1 and LDHA
mRNA expression in Mellm.
(TIF)
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Table 1. Effects of diclofenac on tumor cells.
Early effects Late effects
1 h/2 h 24 h/48 h






Intracellular lactate q*** (0.1) q*** (0.1) q*** (0.1) q*** (0.1)
Extracellular lactate n.s. n.s. Q**/*** (0.1)Q*** (0.1)
Glucose
consumption
n.s. n.s. Q***/** (0.1)Q** (0.1)
Proliferation n.d. n.d. Q*** (0.4) Q** (0.2)
Q*** (0.4)
MYC protein Q*(0.8) n.d. Q*(0.8) Q*(0.4)
Cell death n.d. n.d. q*(0.8) q*/** (0.1)
LDHA mRNA n.s. n.d. Q** (0.1) n.d.
GLUT1 mRNA n.s. n.d. Q** (0.1) n.d.
MCT1 mRNA n.s. n.d. Q** (0.1) n.d.
n.d.: not done; statistical analysis was performed with Student’s t-test, n.s.: no
significant change; ***p,0.001; **p,0.01; *p,0.05.
doi:10.1371/journal.pone.0066987.t001
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